INTELLIGENT BIO SOLUTIONS INC. Q4 FY2021 earnings call

• GBS went public via IPO in December 2020, raising $21.6 million in gross proceeds and listing on NASDAQ. • Awarded $4.7 million grant from the Australian Federal Government for building a high-tech biosensor manufacturing facility, with biosensor platform technology recognized as a National Manufacturing Priority. • Focus on developing Saliva Glucose Biosensor and Saliva SARS-CoV-2 antibody test candidates. • Collaborations with Johns Hopkins Bloomberg School of Public Health and Wyss Institute of Biologically Inspired Engineering at Harvard University. • Conducted global voice of customer survey for diabetes patients, showing positive responses to saliva-based glucose biosensor. • 2021 net loss was $8.5 million, or $0.68 per share, compared to $3.3 million, or $0.37 per share in 2020, due to increased commercialization expenditures.

• Anticipate developing SARS-CoV-2 antibody biosensor for FDA, EUA submission. • Complete clinical protocols for FDA review for Saliva Glucose Biosensor. • Establish validated traceable saliva glucose reference method with Johns Hopkins. • Progress design transfer to manufacturing for Saliva Glucose Biosensor. • Secure out licensing and licensing partnerships for commercialization in APAC. • Complete build of high-tech biosensor facility, with site identification expected by end of current quarter and completion in first half of next year.

• Forward-looking statements involve risks such as developing and commercializing diagnostic tests, realizing commercial benefit from partnerships, and securing regulatory approvals. • Uncertainties related to COVID-19 variant impact and ability to meet regulatory expectations.

Q: What characteristics are being looked for in partners for distribution in the APAC region?

A: Partners need an existing footprint to enter the market quickly and strong relationships with healthcare and regulatory bodies.

Q: Were you able to touch base with the EMA and the FDA to help develop clinical protocols, and how is interaction with agencies?

A: Continuously talk to FDA, in pre-submission process with FDA to ensure protocols are in place, expecting to submit to FDA this year.

Q: What is the timeline for the construction of the manufacturing facility?

A: Site identification expected by end of current quarter, with completion of build anticipated in first half of next year